About us

Biotech Company Specialized in Regenerative Medicine
Main History

Main History

2024
  • Launching of Hutrigel®-RU (Research Use) Product
2023
  • Completing of Hutrigel® Platform Technology Development
  • Completing of Hutrigel®-RU (Research Use) Development
2022
  • New structuring of medical plastic (MP) business division by merging AimTech Inc.
  • Starting human hepatocyte supply service
  • Getting a grant of the Ministry of SMEs and Startups (MSS)
  • Getting a grant of the Korea Medical Device Development Fund
2021
  • Getting IDE approval for the confirmatory clinical trial of BleeFix®
2020
  • Chaging of company name “Lifeliver” to “HLB Cell”
  • Completing the exploratory clinical trial of BleeFix®
2019
  • Getting IDE approval for the exploratory clinical trial of BleeFix®
2018
  • Getting IND approval for phase 2b clinical study of HepaStem
  • Getting IND approval for phase 2b clinical study of bioartificial liver system
2017
  • Completing of phase 1/2a of bioartificial liver system
  • Getting a grant of Korea Institute for Advancement of Technology (KIAT)
2016
  • In-licensing of HepaStem from Promethera (Belgium)
  • Getting a grant of Defense Acquisition Program Administration
2015
  • Getting a developmental orphan drug designation on bioartificial liver system by MFDS
  • In-licensing of surgical hemostat from Utah-Inha DDS & Advance Therapeutics Research Center
2014
  • Getting a grant of Ministry of Health and Welfare
  • Korea's first successful bridging to liver transplant using bioartificial liver support system, LifeLiver®
2013
  • Collaboration of development on bioartificial liver system with SMC (20*20 Project)
2012
  • Getting a grant of Ministry of Health and Welfare
2011
  • Getting a grant of Ministry of National Institute of Food and Drug Safety Evaluation
2009
  • Establishing of Lifeliver Co. Ltd. through comprehensive business transfer of Lifecord Inc.’s R&D and acquisition by HLB
  • Getting IND approval for phase 1/2a study of bioartificial liver system by MFDS